Please login to the form below

Not currently logged in
Email:
Password:

Merck and Co

This page shows the latest Merck and Co news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s Talzenna cleared for breast cancer in Europe

Pfizer’s Talzenna cleared for breast cancer in Europe

Talzenna (talazoparib) has a long way to go to catch AZ and Merck &Co’s Lynparza (olaparib), which is heading for blockbuster sales this year after posting first-quarter sales of ... Array BioPharma for $11.4bn and add another two targeted therapies

Latest news

  • AZ reports stellar results for Lynparza in pancreatic cancer AZ reports stellar results for Lynparza in pancreatic cancer

    Plans to file as soon as possible. AstraZeneca and Merck &Co/MSD have caused a stir at the ASCO congress in Chicago with new data for their PARP inhibitor Lynparza in ... below one year and less than 3% of metastatic pancreatic cancer patients survive

  • AZ invests more in IO with Transgene oncolytic virus deal AZ invests more in IO with Transgene oncolytic virus deal

    to Merck &Co’s Keytruda, BMS’ Opdivo and Roche’s Tecentriq, especially following failures in lung cancer. ... Companies such as AbbVie and J&J both struck deals in the field last year with biotech firms – Turnstone Biologics and BeneVir Biopharm

  • Lilly to withdraw Lartruvo, a first for accelerated approval failures Lilly to withdraw Lartruvo, a first for accelerated approval failures

    Accelerated approvals based on interim data and/or surrogate endpoints is increasingly common occurrence, especially in oncology. ... In recent times, several immunotherapy treatments have failed confirmatory studies. These include Roche’s Tecentriq

  • Gilead's NASH drug fails again Gilead's NASH drug fails again

    A number of other major pharma players such as Pfizer, Novartis, Allergan, Merck &Co and BMS are pursuing a treatment for NASH however, making Gilead far from alone in trying to ... However, the results were far from a home run, as Ocaliva missed a

  • Novo uses voucher for speedy answer on oral semaglutide Novo uses voucher for speedy answer on oral semaglutide

    In the Pioneer programme, people treated with oral semaglutide achieved greater blood glucose reductions compared to Merck &Co's Januvia (sitagliptin) Boehringer Ingelheim and Eli Lilly's Jardiance (empagliflozin) and ... The injectable version of the

More from news
Approximately 43 fully matching, plus 446 partially matching documents found.

Latest Intelligence

  • Vertex: a vision of treating all CF patients worldwide draws closer Vertex: a vision of treating all CF patients worldwide draws closer

    Ex-Merck &Co. scientist Joshua Boger did want the company to pioneer rationale drug discovery and development, however, and after. ... a loss in almost all of its 20+ years, and has cumulative net losses of around $3bn.

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases? ... The cells were gene-edited to lack PD-1, the immune checkpoint targeted by drugs such as Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    EvaluatePharma forecasts that Lynparza (now co-marketed with Merck &Co) will hit annual revenues of $2.2bn by 2024, with Imfinzi expected to reach $3.65bn and Tagrisso leading the way ... This gives it a unique niche in an IO lung cancer market dominated

  • Deal Watch October 2018

    The deal between Merck &Co and Samsung Bioepis has been in place since 2013, when Merck &Co began to work with Samsung Bioepis to produce biosimilars. ... Merck &Co has paid $155m to Samsung Bioepis to cover the investments made so far, plus interest, in

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Checkpoint inhibitors – old and new. The first wave of checkpoint inhibitors targeting PD-(L) 1 and CTLA-4, from Bristol-Myers Squibb, Merck &Co, Roche, AstraZeneca and Merck KGaA/Pfizer, have ... Meanwhile, Incyte’s Merck &Co partnered IDO inhibitor

More from intelligence
Approximately 0 fully matching, plus 41 partially matching documents found.

Latest appointments

  • Weekly industry appointments Weekly industry appointments

    Laboratories and Merck &Co. ... to help take Abcam to the next stage in its development and growth.”.

  • Nabriva Therapeutics appoints chief medical officer Nabriva Therapeutics appoints chief medical officer

    Schranz. Dr Schranz joins Nabriva from Irish biopharma Shire, with nearly two decades of experience in clinical development and medical affairs. ... Her career has seen her hold positions at Shire, ViroPharma, Pfizer, GlaxoSmithKline and Merck &Co.

  • Hansa Medical poaches Vifor Pharma’s CEO Hansa Medical poaches Vifor Pharma’s CEO

    Tulstrup was most recently CEO of Swiss pharmaceutical group Vifor Pharma and prior to this he served as senior vice president, global franchise head at Shire. ... Additionally, Tulstrup has served as CEO of Santaris Pharma, now part of Roche, and in

  • Astellas promotes Anthony Fiordaliso to VP, Americas finance Astellas promotes Anthony Fiordaliso to VP, Americas finance

    He has been with the pharma company since 2010, when he joined from Schering-Plough (now part of Merck &Co) and subsequently held positions of increasing responsibility. ... In his new role Fiordaliso will report to Stephen Knowles, senior vice president

  • Intellia Therapeutics appoints Dr Moncef Slaoui and Dr Frank Verwiel Intellia Therapeutics appoints Dr Moncef Slaoui and Dr Frank Verwiel

    is establishing a Science and Technology Committee, which will be chaired by Slaoui. ... Verwiel has also served at Merck &Co, where he was vice president and was general manager at Merck Sharpe Dohme’s operations in the Netherlands.

More from appointments
Approximately 4 fully matching, plus 33 partially matching documents found.

Latest from PMHub

  • Practical Patient Centricity

    Merck &Co, Sanofi and UCB have identified the competitive advantage that patient centricity brings and are leading the way in its practical implementation. ... Patient centricity is the next market access – and will take 10 years to embed”.

  • Digital Marketing is no Substitute for Sound Strategic Marketing

    With a stronger market access focus, companies can create and implement stronger marketing strategies. ... With no prior blueprint on how to ‘go digital’ in their marketing, early pioneer companies such as Merck &Co.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics